# A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants

> **NCT05254613** · PHASE1 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALXN1830
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05254613
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-12
- **Primary completion:** 2021-01-22
- **Final completion:** 2021-01-22
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The justification of the early termination of the trial: the study is early terminated due to the Coronavirus 2019 epidemic.
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05254613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05254613, "A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05254613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*